期刊文献+

脓毒症免疫抑制的机制及治疗的研究进展 被引量:9

Research progress in mechanism and treatment of sepsis with immunosuppression
下载PDF
导出
摘要 脓毒症存在免疫抑制,其病理生理机制仍不明确,与炎症因子的失衡、免疫细胞数及功能改变有关。改善脓毒症免疫抑制成为治疗脓毒症新的方向,本文就近几年有关脓毒症免疫抑制的机制及治疗手段的研究状况做一综述。 Sepsis comes with immunosuppression. Although it has been known to correlate to the out - of - balance of inflammatory factors, the amount and function of immune cells, the pathophysiological mechanism of immunosuppression in sepsis is still not clear. Improvement of immunosuppression becomes a new direction for the treatment of sepsis. In this paper, the recent studies about the mechanism and treatment of sepsis with immunosuppression are reviewed.
出处 《中国急救医学》 CAS CSCD 北大核心 2013年第8期680-683,共4页 Chinese Journal of Critical Care Medicine
关键词 脓毒症 免疫抑制 机制 治疗 Sepsis Immunosuppression Mechanism Treatment
  • 相关文献

参考文献32

  • 1Monneret G, Finck ME, Venet F, et al. The anti - inflammatory response dominates after septic shock : association of low monocyte HLA - DR expression and high interleukin - 10 concentration [ J ]. Immunol Lett, 2004, 95(2) : 193 -198.
  • 2Seumpia PO, Moldawer LL. Biology of interleukin - 10 and its regulatory roles in sepsis syndromes [ J ]. Crit Care Med, 2005, 33(12Suppl) : $468 - $471.
  • 3Wang TS, Deng JC. Molecular and cellular aspects of sepsis - in- duced [J]. J Mol Med (Berl), 2008, 86 (5) : 495 -506.
  • 4Delano M J, Thayer T, Gabrilovich S, et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection[J]. J Immunol, 2011, 186( 1 ) : 195 -202.
  • 5Lyn -Kew K, Standiford TJ. Immunosuppression in sepsis [ J]. Curt Pharm Des, 2008, 14(19) : 1870 -1881.
  • 6Alves- Filho JC, Spiller F, Cunha FQ. Neutrephil paralysis in sepsis[ J]. Shock, 2010, 34(Suppl 1 ) : 15 - 22.
  • 7Alves- Filho JC, de Freitas A, Spiller F, et al. The role of neu- tmphils in severe sepsis[J]. Shock, 2008, 30(Suppl 1) : 3 -9.
  • 8Chishti AD, Shenton BK, Kirby JA, et al. Neutrophil chemotaxis and receptor expression in clinical septic shock[ J]. Intensive Care Med, 2004, 30(4) : 605 -611.
  • 9Kanfmann I, Hoelzl A, Sehliephake F, et al. Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity[J]. Shock, 2006, 26(3): 254-261.
  • 10Danikas DD, Karakantza M, Theodomu GL, et al. Proguostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression[ J]. Clin ExpImmunol, 2008, 154( 1 ) : 87 -97.

二级参考文献92

  • 1冯国辉,雷志礼,宇鹏,宁新宇,韦中余,李军,刘多辉,董兰,韩暑君,李会光.乌司他丁对原位肝移植术患者围术期肾功能的影响[J].中华麻醉学杂志,2005,25(11):853-855. 被引量:3
  • 2张仁岭,张胜华,冯寿全.四君子汤加大黄对脓毒症大鼠肠黏膜屏障功能的保护作用[J].中国中西医结合消化杂志,2006,14(3):160-163. 被引量:24
  • 3林洪远,管向东,周立新,艾宇航,王可富.乌司他丁、α1胸腺肽联合治疗严重脓毒症——一种新的免疫调理治疗方法的临床研究[J].中华医学杂志,2007,87(7):451-457. 被引量:99
  • 4Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS[J]. Crit Care Med, 1996, 24:1125-1128.
  • 5Fortenberry JD, Paden ML. Extracorporeal therapies in the treat- ment of sepsis : experience and promise[ J]. Semin Pediatr Infect Dis, 2006, 17(2) : 72 -79.
  • 6Opal SM. Hemofiltration - absorption systems for the treatment of experimental sepsis: is it possible to remove the Evil humors're- sponsible for septic shock [ J ]. Crit Care Med, 2001, 28 ( 5 ) : 1681 - 1682.
  • 7Eguchi Y. Plasma dia- filtration for severe sepsis[ J]. Contrib Nephrol, 2010, 166:142-149.
  • 8Zhang LT, Yao YM, Liu JQ, et al. Sodium butyrate prevents le- thality of severe sepsis in rats[ J]. Shock, 2007, 27 (6) : 672 - 677.
  • 9Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents le- thality in mice with established lethal sepsis and systemic inflam- mation[J]. Proc Natl Acad Sci USA, 2002, 99(19) : 12 351 - 12 356.
  • 10Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high - mobility group box 1 [ J ~. Proc Natl Acad Sci USA, 2004, 101 (1) : 296 -301.

共引文献112

同被引文献122

  • 1万献尧.Sepsis诊治进展[J].医师进修杂志,2005,28(8):51-54. 被引量:8
  • 2白祥军,唐朝晖.重视脓毒症的早期诊断与临床干预[J].临床急诊杂志,2006,7(5):215-217. 被引量:5
  • 3林洪远,管向东,周立新,艾宇航,王可富.乌司他丁、α1胸腺肽联合治疗严重脓毒症——一种新的免疫调理治疗方法的临床研究[J].中华医学杂志,2007,87(7):451-457. 被引量:99
  • 4叶发民,孙荣青.脓毒症早期IL-10动态变化及其意义[D].河南:郑州大学,2010:18-20.
  • 5Chello M,Anselmi A,Spadaccio C,et al. Simvastatin increasesneutrophil apoptosis and reduces inflammatory reaction after coro-nary surgery[ J]. Ann Thorac Surg, 2007, 83(4) : 1374 - 1380.
  • 6Kagami S, Kanari H, Suto A, et al. HMG-CoA reductase inhibitorsimvastatin inhibits proinflammatory cytokine production from mu-rine mast cells[ J]. Int Arch Allergy Immunol, 2008, 146( Suppl\):6l -66.
  • 7Bums EM, Smelser LK, Then JE, et al. Short term statin treat-ment improves survival and differentially regulates macrophage -mediated responses to Staphylococcus aureus [ J ] . Curr Pharm Bio-technol, 2013,14(2) : 233 -241.
  • 8Gonzdlez CM, Luna HA, Morales MP, et al. Statin anti - inflam-matory therapy in septic patients[ J]. Cri Care, 2008.
  • 9Krysiak R,Okopie6 B,Herman Z. Effects of HMG - CoA reduc-tase inhibitors on coagulation and fibrinolysis processes [ J ].Drugs, 2003, 63(17) : 1821 -1854.
  • 10Abraham E. Tissue factor inhibition and clinical trial results of tis-sue factor pathway inhibitor in sepsis[ J]. Crit Care Med,2000,28(9 Suppl) : S31 -33.

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部